News

Weekly Recap: 10 Health Press Releases You Need to See
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
PharmExec2d
Eli Lilly to Acquire Verve Therapeutics for $1 Billion
With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...
These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More
Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...
Verve Therapeutics downgraded to Hold from Buy at Canaccord
Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence ...
Lock In The 81.5% Run - Initiating Verve With A Sell
Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly
Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...
Benzinga.com3d
5 Analysts Assess Verve Therapeutics: What You Need To Know
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Verve Therapeutics VERV in the last three months. The table below provides a snapshot of their ...